212 related articles for article (PubMed ID: 35477165)
1. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract][Full Text] [Related]
2. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors.
Mertens RB; Makhoul EP; Li X; Dadmanesh F
Ann Diagn Pathol; 2024 Feb; 68():152226. PubMed ID: 37995412
[TBL] [Abstract][Full Text] [Related]
3. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas.
Müller JH; Plage H; Elezkurtaj S; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Debatin NF; Vettorazzi E; Samtleben H; Hofbauer S; Furlano K; Neymeyer J; Goranova I; Ralla B; Weinberger S; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Bady E
Front Oncol; 2023; 13():1342367. PubMed ID: 38282671
[TBL] [Abstract][Full Text] [Related]
4. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
5. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
6. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus.
Hoppe S; Meder L; Gebauer F; Ullrich RT; Zander T; Hillmer AM; Buettner R; Plum P; Puppe J; Malter W; Quaas A
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230712
[TBL] [Abstract][Full Text] [Related]
7. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
Omori S; Muramatsu K; Kawata T; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Sugino T; Takahashi T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2455-2463. PubMed ID: 34533624
[TBL] [Abstract][Full Text] [Related]
8. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
9. Could trop-2 overexpression indicate tumor aggressiveness among prostatic adenocarcinomas?
Akarken İ; Dere Y
Ann Diagn Pathol; 2021 Feb; 50():151680. PubMed ID: 33341704
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
11. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
Jeon Y; Jo U; Hong J; Gong G; Lee HJ
BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
[TBL] [Abstract][Full Text] [Related]
12. Desmoglein 3 (Dsg3) expression in cancer: A tissue microarray study on 15,869 tumors.
Viehweger F; Azem A; Gorbokon N; Uhlig R; Lennartz M; Dwertmann Rico S; Kind S; Reiswich V; Kluth M; Hube-Magg C; Bernreuther C; Büscheck F; Clauditz TS; Fraune C; Jacobsen F; Krech T; Lebok P; Steurer S; Burandt E; Minner S; Marx AH; Simon R; Sauter G; Menz A; Hinsch A
Pathol Res Pract; 2022 Dec; 240():154200. PubMed ID: 36375372
[TBL] [Abstract][Full Text] [Related]
13. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
[TBL] [Abstract][Full Text] [Related]
14. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract][Full Text] [Related]
15. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
[TBL] [Abstract][Full Text] [Related]
16. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity.
Fong D; Spizzo G; Gostner JM; Gastl G; Moser P; Krammel C; Gerhard S; Rasse M; Laimer K
Mod Pathol; 2008 Feb; 21(2):186-91. PubMed ID: 18084248
[TBL] [Abstract][Full Text] [Related]
17. TROP2 Expression in Sebaceous and Sweat Gland Carcinoma.
Ito T; Hashimoto H; Tanaka Y; Tanegashima K; Murata M; Ichiki T; Iwasaki T; Oda Y; Kaku-Ito Y
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160059
[TBL] [Abstract][Full Text] [Related]
18. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
19. N-glycosylation status of Trop2 impacts its surface density, interaction with claudin-7 and exosomal release.
Kamble PR; Patkar SR; Breed AA; Pathak BR
Arch Biochem Biophys; 2021 Dec; 714():109084. PubMed ID: 34774484
[TBL] [Abstract][Full Text] [Related]
20. Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation.
Zhang B; Gao S; Li R; Li Y; Cao R; Cheng J; Guo Y; Wang E; Huang Y; Zhang K
BMC Cancer; 2020 Aug; 20(1):815. PubMed ID: 32854652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
